SMARCA4 and adenocarcinoma: Typically, patients with SMARCA4-deficient NSCLC clinically present with adenocarcinoma, larger invasive tumor size, a smoking history, and fewer epidermal growth factor receptor (EGFR) mutations (p < 0.05) [5,6].